

## Editorial

- Eribulin: Rediscovering Tubulin as an Anticancer Target.** Antonio Jimeno.....3903  
  *Commentary on Goel et al., p. 4207 and Tan et al., p. 4213*

## CCR Translations

- Toward an Effective Targeted Chemotherapy for Multiple Myeloma.** Andrew G. Polson  
and Mark X. Sliwkowski .....3906  
  *Commentary on Ikeda et al., p. 4028*

## CCR Practice of Translational Oncology

- Successes and Challenges in Translational Research: The Development of Targeted Therapy  
for Gastrointestinal Stromal Tumours.** Daniel J. Renouf, Lora Wilson, and Charles D. Blanke .....3908

## Molecular Pathways

- Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer.** Teresa A. Soucy,  
Peter G. Smith, and Mark Rolfe .....3912

## CCR Special Focus

- From the Editor.** Susan E. Bates.....3917
- Epigenetic Modifiers: Basic Understanding and Clinical Development.** Richard L. Piekarz  
and Susan E. Bates.....3918
- Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications.** Michael T. McCabe,  
Johann C. Brandes, and Paula M. Vertino.....3927
- Targeting DNA Methylation.** Jean-Pierre J. Issa and Hagop M. Kantarjian .....3938
- Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and  
Potential Clinical Implications.** David S. Schrupp.....3947
- Clinical Studies of Histone Deacetylase Inhibitors.** H. Miles Prince, Mark J. Bishton,  
and Simon J. Harrison.....3958
- Rational Combinations Using HDAC Inhibitors.** Michael Bots and Ricky W. Johnstone.....3970

## Human Cancer Biology

- Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer.** Olga Dakhova,  
Mustafa Ozen, Chad J. Creighton, Rile Li, Gustavo Ayala, David Rowley, and Michael Ittmann.....3979
- GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer.**  
Debby M.E.I. Hellebrekers, Marjolein H.F.M. Lentjes, Sandra M. van den Bosch, Veerle Melotte,  
Kim A.D. Wouters, Kathleen L.J. Daenen, Kim M. Smits, Yoshimitsu Akiyama, Yasuhito Yuasa,  
Silvia Sanduleanu, Carolina A.J. Khalid-de Bakker, Daisy Jonkers, Matty P. Weijnenberg, Joost Louwagie,  
Wim van Criekinge, Beatriz Carvalho, Gerrit A. Meijer, Stephen B. Baylin, James G. Herman,  
Adriaan P. de Bruïne, and Manon van Engeland.....3990
- MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis  
Inhibitor.** Jinsong Li, Hongzhang Huang, Lijuan Sun, Mei Yang, Chaobin Pan, Weiliang Chen,  
Donghui Wu, Zhaoyu Lin, Chunxian Zeng, Yandan Yao, Peter Zhang, and Erwei Song .....3998
- Locked Nucleic Acid *In situ* Hybridization Analysis of miR-21 Expression during Colorectal  
Cancer Development.** Nobutake Yamamichi, Ryoichi Shimomura, Ken-ichi Inada, Kouhei Sakurai,  
Takeshi Haraguchi, Yuka Ozaki, Shuji Fujita, Taketoshi Mizutani, Chihiro Furukawa,  
Mitsuhiro Fujishiro, Masao Ichinose, Kazuya Shioyama, Yutaka Tsutsumi, Masao Omata,  
and Hideo Iba .....4009

---

**Fibroblast Growth Factor Receptor 2–Positive Fibroblasts Provide a Suitable Microenvironment for Tumor Development and Progression in Esophageal Carcinoma.** Chunyu Zhang, Li Fu, Jianhua Fu, Liang Hu, Hong Yang, Tie-Hua Rong, Yan Li, Haibo Liu, Song-Bin Fu, Yi-Xin Zeng, and Xin-Yuan Guan.....4017

## Cancer Therapy: Preclinical

---

**The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells *In vitro* and *In vivo*.** Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, Robert J. Lutz, Hiroshi Yasui, Yutaka Okawa, Tanyel Kiziltepe, Sonia Vallet, Samantha Pozzi, Loredana Santo, Giulia Perrone, Yu-Tzu Tai, Diana Cirstea, Noopur S. Raje, Christoph Uherek, Benjamin Dälken, Silke Aigner, Frank Osterroth, Nikhil Munshi, Paul Richardson, and Kenneth C. Anderson.....4028

**Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma.** Ayad M. Al-Katib, Amro Aboukameel, Ramzi Mohammad, Marie-Christine Bissery, and Claudia Zuany-Amorim .....4038

**CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy.** Rudi Bao, Cheng-Jung Lai, Hui Qu, Dagong Wang, Ling Yin, Brian Zifcak, Ruzanna Atoyian, Jing Wang, Maria Samson, Jeffrey Forrester, Steven DellaRocca, Guang-Xin Xu, Xu Tao, Hai-Xiao Zhai, Xiong Cai, and Changgeng Qian.....4046

**Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer.** Nichole R. Dean, J. Robert Newman, Emily E. Helman, Wenyue Zhang, Seena Safavy, D.M. Weeks, Mark Cunningham, Linda A. Snyder, Yi Tang, Li Yan, Lacey R. McNally, Donald J. Buchsbaum, and Eben L. Rosenthal .....4058

**High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model.** Giuseppe Floris, Maria Debiec-Rychter, Raf Sciot, Cristiana Stefan, Steffen Fieuws, Kathleen Machiels, Peter Atadja, Agnieszka Wozniak, Gavino Faa, and Patrick Schöffski .....4066

**Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells.** Mitsuru Miyachi, Naoki Kakazu, Shigeki Yagyu, Yoshiki Katsumi, Satoko Tsubai-Shimizu, Ken Kikuchi, Kunihiko Tsuchiya, Tomoko Iehara, and Hajime Hosoi .....4077

**Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage.** Roberta Mortarini, Claudia Vegetti, Alessandra Molla, Flavio Arienti, Fernando Ravagnani, Andrea Maurichi, Roberto Patuzzo, Mario Santinami, and Andrea Anichini .....4085

**Targeting GIPC/Synectin in Pancreatic Cancer Inhibits Tumor Growth.** Michael H. Muders, Pawan K. Vohra, Shamit K. Dutta, Enfeng Wang, Yasuhiro Ikeda, Ling Wang, D. Gomika Udugamasooriya, Adnan Memic, Chamila N. Rupasinghe, Gustavo B. Baretton, Daniela E. Aust, Silke Langer, Kaustubh Datta, Michael Simons, Mark R. Spaller, and Debabrata Mukhopadhyay.....4095

**MMP11: A Novel Target Antigen for Cancer Immunotherapy.** Daniela Peruzzi, Federica Mori, Antonella Conforti, Domenico Lazzaro, Emanuele De Rinaldis, Gennaro Ciliberto, Nicola La Monica, and Luigi Aurisicchio.....4104

**Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration.** Anthony L. Schwartz, Ramiro Malgor, Eric Dickerson, Ashani T. Weeraratna, Andrzej Slominski, Jacobo Wortsman, Norikazu Harii, Aimee D. Kohn, Randall T. Moon, Frank L. Schwartz, Douglas J. Goetz, Leonard D. Kohn, and Kelly D. McCall .....4114

**Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen.** Rakesh Kumar, Hao Zhang, Caroline Holm, Ratna K. Vadlamudi, Goran Landberg, and Suresh K. Rayala.....4123

**Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicentric Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer.** Kellie Matthews, Patricia E. Noker, Baohong Tian, Sheila D. Grimes, Ronna Fulton, Karen Schweikart, Raymond Harris, Rose Aurigemma, Minghui Wang, Mack N. Barnes, Gene P. Siegal, Akseli Hemminki, Kurt Zinn, David T. Curiel, and Ronald D. Alvarez.....4131

---

**Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer.** N. V. Rajeshkumar, Aik Choon Tan, Elizabeth De Oliveira, Chris Womack, Helen Wombwell, Shethah Morgan, Madhuri V. Warren, Jill Walker, Tim P. Green, Antonio Jimeno, Wells A. Messersmith, and Manuel Hidalgo .....4138

**Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab.** Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, Tom Truong, Peter M. Haverty, Jeffrey Eastham-Anderson, Nicholas Lewin-Koh, Bert Gunter, Marcia Belvin, Lesley J. Murray, Lori S. Friedman, Mark X. Sliwkowski, and Klaus P. Hoeflich .....4147

## Imaging, Diagnosis, Prognosis

**High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma.** Valsamo K. Anagnostou, Gerold Bepler, Konstantinos N. Syrigos, Lynn Tanoue, Scott Gettinger, Robert J. Homer, Daniel Boffa, Frank Detterbeck, and David L. Rimm .....4157

**A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide.** Sharon A. Glynn, Brenda J. Boersma, Tiffany M. Howe, Hege Edvardsen, Stephanie B. Geisler, Julie E. Goodman, Lisa A. Ridnour, Per E. Lønning, Anne-Lise Børresen-Dale, Bjorn Naume, Vessela N. Kristensen, Stephen J. Chanock, David A. Wink, and Stefan Ambs .....4165

**Methylation of RASSF1A, RASSF2A, and HIN-1 Is Associated with Poor Outcome after Radiotherapy, but not Surgery, in Oral Squamous Cell Carcinoma.** Kuo-Hao Huang, Shiang-Fu Huang, I-How Chen, Chun-Ta Liao, Hung-Ming Wang, and Ling-Ling Hsieh .....4174

**Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients.** Bas Kreike, Hans Halfwerk, Nicola Armstrong, Peter Bult, John A. Foekens, Sanne C. Veltkamp, Dimitry S.A. Nuyten, Harry Bartelink, and Marc J. van de Vijver .....4181

**Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors.** Salvatore Romeo, Maria Debiec-Rychter, Martine Van Glabbeke, Heidi Van Paassen, Paola Comite, Ronald Van Eijk, Jan Oosting, Jaap Verweij, Philippe Terrier, Ulrike Schneider, Raf Sciot, Jean Yves Blay, and Pancras C.W. Hogendoorn on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group .....4191

**Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from Radiation Therapy Oncology Group 0128.** Joanne B. Weidhaas, Shu-Xia Li, Kathryn Winter, Janice Ryu, Anuja Jhingran, Bridgette Miller, Adam P. Dicker, and David Gaffney .....4199

## Cancer Therapy: Clinical

**A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies.** Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, and Chris H. Takimoto .....4207

**Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors.** Antoinette R. Tan, Eric H. Rubin, Diana C. Walton, Dale E. Shuster, Y. Nancy Wong, Fang Fang, Simon Ashworth, and Lee S. Rosen .....4213

**Phase I Trial of Pazopanib in Patients with Advanced Cancer.** Herbert I. Hurwitz, Afshin Dowlati, Shermini Saini, Shawna Savage, A. Benjamin Suttle, Diana M. Gibson, Jeffrey P. Hodge, Elmar M. Merkle, and Lini Pandite .....4220

**Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors.** Roos L. Oostendorp, Alwin Huitema, Hilde Rosing, Robert S. Jansen, Rob ter Heine, Marianne Keessen, Jos H. Beijnen, and Jan H.M. Schellens .....4228

---

**Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers.** Tomonori Tanei, Koji Morimoto, Kenzo Shimazu, Seung Jin Kim, Yoshio Tanji, Tetsuya Taguchi, Yasuhiro Tamaki, and Shinzaburo Noguchi .....4234

## Susceptibility and Prevention


---

**Mixed Tocopherols Prevent Mammary Tumorigenesis by Inhibiting Estrogen Action and Activating PPAR- $\gamma$ .** Hong Jin Lee, Jihyeung Ju, Shiby Paul, Jae-Young So, Andrew DeCastro, Amanda Smolarek, Mao-Jung Lee, Chung S. Yang, Harold L. Newmark, and Nanjoo Suh .....4242

---

## About the Cover

Reactive stroma from prostate cancer and normal prostatic stroma was laser captured, RNAs were amplified and gene expression analyzed using expression microarrays. A total of 1141 genes were differentially expressed in reactive compared with normal stroma. The Human Protein Reference Database catalogue of over 35,000 known physical protein-protein interactions was queried to determine how the reactive stroma-associated genes relate to each other in terms of interactions between their associated proteins. A total of 292 interactions were visualized as a graphical network. A view of the central node is shown. For further details, please see Dakhova and colleagues on page 3979 in this issue.



# Clinical Cancer Research

**15 (12)**

*Clin Cancer Res* 2009;15:3903-4249.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/15/12>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/15/12>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.